Speak Up: Ask Congress to Block Medicare Reimbursement Cuts
Rheumatologists may need to downsize and restrict patient care if Congress doesn’t act to block significant cuts to Medicare reimbursement rates totaling 9.75% in 2022. (Source: The Rheumatologist)
Source: The Rheumatologist - October 22, 2021 Category: Rheumatology Authors: Carina Stanton Tags: Legislation & Advocacy ACR advocacy Center for Medicare & Medicaid Services (CMS) Congressional outreach Medicare reimbursement rate Physician Fee Schedule (PFS) Sequestration Source Type: research

TNF Inhibitors & Pregnancy: How Well Does the Treatment Guidance Work?
Ghalandari et al. sought to validate the guidance outlined by EULAR for the use of anti-rheumatic drugs during pregnancy, finding that following its guidance for tumor necrosis factor inhibitors led to no or low concentrations of these agents in cord blood. (Source: The Rheumatologist)
Source: The Rheumatologist - October 21, 2021 Category: Rheumatology Authors: Michele B. Kaufman, PharmD, BCGP Tags: DMARDs & Immunosuppressives Drug Updates EULAR pregnancy pregnant women TNF inhibitors TNFi Source Type: research

FDA Approves Cyltezo, an Interchangeable Biosimilar to Humira
On Oct. 15, the U.S. Food & Drug Administration (FDA) approved the first interchangeable biosimilar product to treat certain inflammatory diseases. Cyltezo (adalimumab-adbm), originally approved in August 2017, is both biosimilar to and interchangeable with (i.e, may be substituted for) its reference product Humira (adalimumab) for Cyltezo’s approved uses. Cyltezo is the second interchangeable biosimilar... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 19, 2021 Category: Rheumatology Authors: U.S. Food & Drug Administration Tags: Biologics & Biosimilars Drug Updates adalimumab adalimumab-adbm Cyltezo FDA approval Humira U.S. Food and Drug Administration (FDA) Source Type: research

New Supplement to The Rheumatologist Highlights Psoriatic Arthritis Advances
It feels like a long decade has passed since March 2020. At The Rheumatologist, we closed out 2020 with a special supplement on gout. Physician Editor Phil Seo, MD, MHS, kicked off that supplement with, “COVID-19. Black Lives Matter. A new gout guideline. These are some of the things 2020 ushered in. And we’re unlikely... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 15, 2021 Category: Rheumatology Authors: Ethan Craig, MD, MHS Tags: Conditions PsA Resource Center Psoriatic Arthritis Source Type: research

Minimizing Disease Activity in Psoriatic Arthritis
The use of objective, validated outcome measures to track progress in symptom control for patients with psoriatic arthritis was discussed in a session at the 2019 ACR/ARP Annual Meeting titled Optimizing Outcomes in Psoriatic Arthritis: A Domain-Based Strategy. In the years since this presentation, additional research has helped supply greater insights into this topic and... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 15, 2021 Category: Rheumatology Authors: Jason Liebowitz, MD Tags: Conditions PsA Resource Center Psoriatic Arthritis tapering Source Type: research

A Dematologist ’ s Perspective on Choosing an Anti-Psoriatic Drug
We are fortunate to have clinical practice guidelines for the management of psoriasis and psoriatic arthritis (PsA) from multiple organizations to help navigate today’s rapidly evolving therapeutic landscape. We are further fortunate to have multiple specialists to manage these conditions: rheumatologists and dermatologists. However, multiple guidelines, multiple drugs and multiple specialists can create a paradox... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 15, 2021 Category: Rheumatology Authors: Samantha C. Shapiro, MD Tags: Biologics & Biosimilars Conditions DMARDs & Immunosuppressives PsA Resource Center Psoriatic Arthritis Source Type: research

Trial Pits Upadacitinib vs. Adalimumab for Psoriatic Arthritis
As treatments for psoriatic arthritis (PsA) emerge, a clinical trial comparing the Janus kinase (JAK) inhibitor upadacitinib and the tumor necrosis fac­tor (TNF) inhibitor adalimumab provided some new insights. Published earlier this year in The New England Journal of Medi­cine, the SELECT-PsA 1, double-blind, phase 3 trial found that a 30 mg dose of upadacitinib... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 14, 2021 Category: Rheumatology Authors: Vanessa Caceres Tags: Conditions Drug Updates Safety adalimumab PsA Resource Center Psoriatic Arthritis upadacitinib Source Type: research

Tips for Transitioning Patients from Pediatric to Adult Rheumatology Care
Approximately 50% of young adult patients with childhood-onset rheumatic diseases become lost to follow-up within the first year of transferring to adult rheumatology care, mirroring the statistics of other subspecialties.1,2 One of the challenges cited most consistently by young adult patients and their families relates to differences between rheumatology care delivery in the pediatric and... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 14, 2021 Category: Rheumatology Authors: Sarah D. Bayefsky, MD, Kimberly DeQuattro, MD, & Rebecca E. Sadun, MD, PhD Tags: Conditions Drug Updates Safety adalimumab PsA Resource Center Psoriatic Arthritis upadacitinib Source Type: research

Fall 2021 ’s Awards, Appointments & Announcements in Rheumatology
Jeffrey Siegel, MD, Assumes New Position as Director for New Office of Drug Evaluation Sciences at the FDA On Feb. 16, Jeffrey Siegel, MD, became the director of the recently created Office of Drug Evaluation Sciences at the U.S. Food & Drug Administration (FDA). The move, he says, “puts together many of the different things... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 14, 2021 Category: Rheumatology Authors: Gretchen Henkel Tags: Awards Dr. Carol Ziminski Dr. Gordon Hutchinson Dr. Jason Springer Dr. Jeffrey Siegel Dr. Sebastian Sattui Source Type: research

An Ethical Dilemma: To Test Or Not to Test?
“Maria” is a 54-year-old woman with seropositive rheumatoid arthritis, as well as hypertension and hyperlipidemia. She is a new patient in your clinic following a move across the country to live with her children on a farm in a rural area of the Midwest. At her first visit, three months ago, you and Maria agreed—through... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 14, 2021 Category: Rheumatology Authors: Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS Tags: Ethics Patient Perspective Professional Topics Source Type: research

Who You Know Matters … But Not with the ARP
Over the past 16 months, the world has shone a bright light on the importance of diversity, equity and inclusion (DEI). Although the College has been focused on diversity initiatives since 2020, the interprofessional division of the College, the ARP, has recently taken a deeper dive into DEI initiatives in its processes, procedures and volunteering.... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 14, 2021 Category: Rheumatology Authors: Janet L. Poole, PhD, OTR/L, & Christine Stamatos, DNP, ANP-C Tags: Interprofessional Perspective Professional Topics Association of Rheumatology Professionals (ARP) Diversity Equity inclusion Volunteering Source Type: research

New ACR Subcommittee Will Advance Diversity, Equity & Inclusion
Diversity, equity and inclusion (DEI) are the focus of a new ACR/ARP subcommittee of the Collaborative Initiatives (COIN) Special Committee. The 13-member group will explore strategies to increase diversity in the rheumatology workforce pipeline and reduce implicit bias in such organizational processes as speaker recruitment and abstract review. “There is a new awareness at the... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 14, 2021 Category: Rheumatology Authors: Susan Bernstein Tags: From the College Home Slider Professional Topics Workforce Diversity Equity inclusion Source Type: research

Case Report: Is It Castleman Disease, or Castleman-Like?
The difference between Castle­man disease and Castleman-like disease may be subtle, but it comes with significant ramifications. Case Presentation This case involves a pregnant 19-year-old woman who presents over multiple hospitalizations with concerns for systemic lupus erythematosus and macrophage activation syndrome. At 36 weeks’ gestation, the patient’s weight had dropped from 215 lbs. to 170... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 14, 2021 Category: Rheumatology Authors: Philip Chu, MD, RhMSUS, Mithu Maheswaranathan, MD, Jadee L. Neff, MD, PhD, & Rebecca E. Sadun, MD, PhD Tags: Conditions Home Slider SLE (Lupus) case report castleman disease Source Type: research

The Dual-Target Strategy in Rheumatoid Arthritis
As treatments for psoriatic arthritis (PsA) emerge, a clinical trial comparing the Janus kinase (JAK) inhibitor upadacitinib and the tumor necrosis fac­tor (TNF) inhibitor adalimumab provided some new insights. Published earlier this year in The New England Journal of Medi­cine, the SELECT-PsA 1, double-blind, phase 3 trial found that a 30 mg dose of upadacitinib... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 14, 2021 Category: Rheumatology Authors: Ricardo J.O. Ferreira, RN, PhD; Leonard H. Calabrese, DO; & José A.P. Da Silva, MD, PhD Tags: Conditions Patient Perspective Rheumatoid Arthritis Disease Activity Score (DAS) patient centeredness shared decision making Speak Out Rheumatology Treat-to-Target Source Type: research

Revisionist History: Seat Belts & Resistance to Public Health Measures
Some were furious. State by state, laws were enacted to ensure compliance. In most states, the laws were accompanied by a modest fine, as an added incentive. By the time the laws were written, most understood they were based on good science and common sense. The potential to save lives and prevent tragedy was finally... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 14, 2021 Category: Rheumatology Authors: Philip Seo Tags: Rheuminations COVID-19 vaccination vaccine hesitancy Source Type: research

Healthcare Accessibility for People with Rheumatic Disease in New Haven, CT
The COVID-19 pandemic exacerbated wide disparities that exist in the U.S. healthcare system. During the pandemic, the clinical practice in the Section of Rheumatology, Allergy & Immunology at Yale School of Medicine (YSM), New Haven, Conn., rapidly pivoted from face-to-face visits to telehealth to keep our patients and providers safe. Many patients quickly adapted and... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 14, 2021 Category: Rheumatology Authors: Vaidehi R. Chowdhary, MD, & Jane E. Dee, BA, MALS Tags: Home Slider Patient Perspective Practice Management Access to care COVID-19 Disparities Dr. Lenore Buckley telehealth Source Type: research

How Does Reduced-Dose Glucocorticoids Plus Rituximab Affect ANCA-Associated Vasculitis?
Furuta et al. evaluated the benefits of reducing glucocorticoid doses during remission induction for patients with ANCA-associated vasculitis. The researchers found a reduced-dose-glucocorticoid-plus-rituximab regimen was noninferior to a regimen of high-dose glucocorticoids plus rituximab in these patients. (Source: The Rheumatologist)
Source: The Rheumatologist - October 13, 2021 Category: Rheumatology Authors: Lara C. Pullen, PhD Tags: Conditions Vasculitis ANCA-Associated Vasculitis Glucocorticoids Remission rituximab Source Type: research

Psoriatic Arthritis Treatment Update
About 30% of patients with psoriasis have psoriatic arthritis (PsA), a complex, multi-faceted, chronic, inflammatory musculoskeletal and skin disease for which the treatment has changed considerably over the past few years.1 Biosimilars and other new drugs have become a therapeutic turning point for many patients suffering from rheumatic illnesses, including PsA. The treatment of PsA... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 13, 2021 Category: Rheumatology Authors: Mary Choy, PharmD, BCGP, FASHP Tags: Conditions Drug Updates Guidelines PsA Resource Center Psoriatic Arthritis Source Type: research

Vasculitis Guidelines in Focus, Part 5: Takayasu Arteritis
Andy Abril, MD, a lead author of the ACR/VF guideline for Takayasu arteritis (TAK), discusses the recommendations for TAK. (Source: The Rheumatologist)
Source: The Rheumatologist - October 11, 2021 Category: Rheumatology Authors: Michael Putman, MD Tags: Conditions Guidelines Vasculitis Takayasu arteritis (TAK) Vasculitis Foundation Source Type: research

Lively, Practical Training at Advocacy 101
Amid spirited discussions on drug pricing and insurance challenges, participants got hands-on experience advocating for current bills regulating prior authorization and pharmacy benefit managers. (Source: The Rheumatologist)
Source: The Rheumatologist - October 11, 2021 Category: Rheumatology Authors: Leslie Mertz, PhD Tags: Legislation & Advocacy Advocacy 101 Advocates for Arthritis Amanda Schnell Deepika Singh Samuel Gagne Source Type: research

The Latest Psoriatic Arthritis Management Insights
An overview of the research to date and the ways in which such evidence can be used to guide the treatment of patients was presented at the 2019 ACR/ARP Annual Meeting in a session titled Optimizing Outcomes in Psoriatic Arthritis: A Domain-Based Strategy. In the years since this presentation, additional research has helped supply greater... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 11, 2021 Category: Rheumatology Authors: Jason Liebowitz, MD Tags: Conditions PsA Resource Center Psoriatic Arthritis Source Type: research

FDA Approves Avacopan for the Treatment of ANCA-Associated Vasculitis
On Oct. 8, ChemoCentryx Inc. announced that the U.S. Food & Drug Administration (FDA) has approved avacopan (TAVNEOS), an orally administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis), specifically granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (the two main forms... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 8, 2021 Category: Rheumatology Authors: ChemoCentryx Tags: Biologics & Biosimilars Conditions Drug Updates Vasculitis avacopan Source Type: research

A Look Inside the Advocate Experience at Advocates for Arthritis
Eric Dein, MD, shared rheumatology perspectives with five congressional offices on Sept. 28 as part of the virtual Hill Day. Read his hour-by-hour account, including staffer education, legislative requests and prior authorization woes. (Source: The Rheumatologist)
Source: The Rheumatologist - October 8, 2021 Category: Rheumatology Authors: Eric Dein, MD Tags: Legislation & Advocacy Advocates for Arthritis Congressional outreach Source Type: research

Fiscal Year 2022 ICD-10-CM Codes Now in Effect
New and updated FY22 diagnosis codes became effective for encounters on or after Oct. 1, 2021, including key updates for Sjögren syndrome and non-radiographic axial spondyloarthritis. (Source: The Rheumatologist)
Source: The Rheumatologist - October 8, 2021 Category: Rheumatology Authors: From the College Tags: Billing/Coding Spondyloarthritis Systemic Inflammatory Syndromes ICD-10 low back pain non-radiographic axial spondyloarthritis Sjögren's syndrome Source Type: research

Guselkumab Promising in Patients with PsA
Initial 24-week data from a study of patients with psoriatic arthritis (PsA) show that treatment with guselkumab improved symptoms and resulted in a higher ACR20 response than placebo in patients who could not tolerate, or did not respond to, treatment with a tumor necrosis factor inhibitor (TNFi). (Source: The Rheumatologist)
Source: The Rheumatologist - October 7, 2021 Category: Rheumatology Authors: Michele B. Kaufman, PharmD, BCGP Tags: Biologics & Biosimilars Drug Updates Meeting Reports EULAR guselkumab Psoriatic Arthritis Source Type: research

Dusty Trades: Inorganic Dust Exposure During Military Service May Be an Occupational Risk Factor for RA
Mounting evidence indicates that exposure to inorganic dust is a risk factor for the development of autoimmune diseases. According to a recent study, dust exposure during military service in dusty environments represents an occupational and environmental risk and was associated with a 10% increased risk of developing RA. (Source: The Rheumatologist)
Source: The Rheumatologist - October 7, 2021 Category: Rheumatology Authors: Lara C. Pullen, PhD Tags: Conditions Rheumatoid Arthritis ACR Open Rheumatology exposure inorganic dust exposure job Military Rheumatoid Arthritis (RA) Risk Factors Source Type: research

Live Varicella Zoster Vaccine Safe, Effective with TNF Inhibitors
(Reuters Health)—Adults 50 years and older who take tumor necrosis factor inhibitors (TNFi’s) for a range of inflammatory disorders can receive effective protection from shingles with a live varicella zoster vaccine, a clinical trial suggests.1 Researchers randomized 617 participants receiving TNFi’s in a 1:1 ratio to receive either the Zostavax live varicella zoster vaccine or... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 6, 2021 Category: Rheumatology Authors: Lisa Rapaport Tags: Biologics & Biosimilars Drug Updates live vaccine varicella zoster vaccine varicella zoster virus Source Type: research

Severe COVID-19 May Trigger Autoimmunity
Reuters)—Severe COVID-19 may trick the immune system into producing autoantibodies that have the potential to eventually attack healthy tissue and cause inflammatory diseases, researchers warned in a paper published in Nature Communications.1 They found autoantibodies in blood samples from roughly 50% of the 147 COVID-19 patients they studied, but in fewer than 15% of 41... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 6, 2021 Category: Rheumatology Authors: Reuters Staff Tags: Conditions autoimmunity COVID-19 Source Type: research

Practical Ways to Manage Cardiovascular Risk in Patients with Psoriatic Arthritis
Increased cardiovascular (CV) risk in patients with rheumatic disease is old news. Over the past decade, a multitude of studies have demonstrated elevated CV risk in a variety of conditions: systemic lupus erythematosus, rheumatoid arthritis and psoriatic arthritis (PsA), to name a few. The risk in patients with rheumatic disease seems to be linked to... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - October 5, 2021 Category: Rheumatology Authors: Samantha C. Shapiro, MD Tags: Conditions PsA Resource Center Psoriatic Arthritis Source Type: research

The Role of ANA Positivity in Patients with RA
Recent research suggests patients with RA and a positive test for anti-nuclear antibody (ANA) may not have a different disease course than patients with RA who test negative for ANA. However, these patients may experience different treatment courses. (Source: The Rheumatologist)
Source: The Rheumatologist - September 28, 2021 Category: Rheumatology Authors: Susan Bernstein Tags: Conditions Rheumatoid Arthritis ANA ANA-positive RA anti-nuclear antibody Rheumatoid Arthritis (RA) Source Type: research

Nonserious Infection Rates with Biologics Used to Treat RA
Bechman et al. set out to describe the frequency and predictors of nonserious infections and compare incidence rates across biologic DMARDs. They found all bDMARDs are associated with a greater risk of nonserious infection, with differences observed between agents. Although unmeasured confounding must be considered, the magnitude of effect is large. (Source: The Rheumatologist)
Source: The Rheumatologist - September 27, 2021 Category: Rheumatology Authors: Arthritis & Rheumatology Tags: Conditions Rheumatoid Arthritis Arthritis & Rheumatology biologic disease-modifying antirheumatic drugs biologic DMARD Infection Rheumatoid Arthritis (RA) Source Type: research

Experts Share Insights & Advice on Reproductive Health for Patients with Rheumatic Disease
Contraception, disease control, family planning and managing life with an infant—four experts addressed these concerns and more for patients with rheumatic disease during a special online webinar. (Source: The Rheumatologist)
Source: The Rheumatologist - September 24, 2021 Category: Rheumatology Authors: Kelly Tyrrell Tags: Conditions contraceptive family planning patient care pregnancy reproductive health Rheumatic Disease Awareness Month (RDAM) Source Type: research

Vasculitis Guidelines in Focus, Part 4: Polyarteritis Nodosa
In July, the ACR—in concert with the Vasculitis Foundation (VF)—released three new vasculitis guidelines, one each on: 1) anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, 2) giant cell arteritis and Takayasu arteritis, and 3) polyarteritis nodosa.1-3 The guideline development process is complex. For the vasculitis guidelines, this process kicked off in June 2017, when the core... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - September 22, 2021 Category: Rheumatology Authors: Michael Putman, MD Tags: Conditions Vasculitis Guidelines polyarteritis nodosa Vasculitis Foundation Source Type: research

Rheumatologists Saw a Gain in Compensation in 2020
Although patient volume temporarily declined due to the COVID-19 pandemic, rheumatologists saw a larger increase in compensation in 2020 than in 2019, according to a recent Medscape survey. (Source: The Rheumatologist)
Source: The Rheumatologist - September 22, 2021 Category: Rheumatology Authors: Carina Stanton Tags: Professional Topics Compensation COVID-19 Medscape survey rheumatologists rheumatology Salary Source Type: research

Tocilizumab Effective for Early SSc-Associated Interstitial Lung Disease
Treatment with tocilizimab preserved lung function in patients with systemic sclerosis (SSc) and interstitial lung disease (ILD) regardless of a patient’s level of lung involvement, according to a recent study. (Source: The Rheumatologist)
Source: The Rheumatologist - September 22, 2021 Category: Rheumatology Authors: Lara C. Pullen, PhD Tags: Conditions DMARDs & Immunosuppressives interstitial lung disease (ILD) systemic sclerosis (SSc) systemic sclerosis-associated ILD tocilizumab Source Type: research

Oral CBD Fails to Relieve Pain from Hand OA & PsA
NEW YORK (Reuters Health)—Lower doses of cannabidiol (CBD) failed to provide any meaningful reduction in pain when added to other analgesic therapy in patients with hand osteoarthritis (OA) or psoriatic arthritis (PsA) in a randomized, placebo-controlled study from Denmark.1 Writing in the journal, Pain, Jonathan Vela, MD, and colleagues of Aalborg University note that CBD... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - September 22, 2021 Category: Rheumatology Authors: Reuters Staff Tags: Analgesics Drug Updates cannabidiol (CBD) hand osteoarthritis hand pain PsA Psoriatic Arthritis Source Type: research

Inspired by Healthcare Disparities to Advocate for Change
Seeing the challenges her rural patients faced in accessing specialty care, Amanda Schnell, MD, was inspired to make advocacy an integral part of her work at the University of Alabama at Birmingham. (Source: The Rheumatologist)
Source: The Rheumatologist - September 21, 2021 Category: Rheumatology Authors: Leslie Mertz, PhD Tags: Legislation & Advocacy Profiles Amanda Schnell Government Affairs Committee (GAC) healthcare disparities Source Type: research

RheumPAC Advocacy Fund: Effecting Change
Professional practices, state societies and other organizations can support RheumPAC’s work with corporate funds through the RheumPAC Advocacy Fund. (Source: The Rheumatologist)
Source: The Rheumatologist - September 16, 2021 Category: Rheumatology Authors: From the College Tags: American College of Rheumatology Legislation & Advocacy ACR advocacy RheumPAC RheumPAC Advocacy Fund Source Type: research

FDA Grants Octapharma 7-Year Market Exclusivity for Octagam 10%
The FDA has granted a seven-year marketing exclusivity for Octagam 10%, a 10% solution of a human intravenous immunoglobulin (IVIG) that treats adults with dermatomyositis. (Source: The Rheumatologist)
Source: The Rheumatologist - September 15, 2021 Category: Rheumatology Authors: Michele B. Kaufman, PharmD, BCGP Tags: Drug Updates Pharma Co. News dermatomyositis dermatomyositis (DM) FDA FDA approval intravenous human immunoglobulin IVIg Octagam 10% U.S. Food and Drug Administration (FDA) Source Type: research

FDA Grants IVIG 7-Year Market Exclusivity to Treat Adults with Dermatomyositis
The FDA has granted a seven-year marketing exclusivity for Octagam 10%, a 10% solution of a human intravenous immunoglobulin (IVIG) that treats adults with dermatomyositis. (Source: The Rheumatologist)
Source: The Rheumatologist - September 15, 2021 Category: Rheumatology Authors: Michele B. Kaufman, PharmD, BCGP Tags: Drug Updates Pharma Co. News dermatomyositis dermatomyositis (DM) FDA FDA approval intravenous human immunoglobulin IVIg Octagam 10% U.S. Food and Drug Administration (FDA) Source Type: research

Rituximab for Children with Lupus Nephritis
This study highlights the importance of collaborative effort in developing CTPs (Consensus Treatment Plans) for pediatric LN,” the authors write in... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - September 15, 2021 Category: Rheumatology Authors: Lorraine L. Janeczko Tags: Biologics & Biosimilars Conditions SLE (Lupus) Pediatrics Source Type: research

ACR Responds to 2022 Medicare Physician Fee Schedule Proposed Rule
Rheumatology leaders are encouraged by continued implementation of E/M coding changes, telehealth flexibilities and rheumatology-specific MIPS Value Pathway, but have concerns regarding conversion factor reductions and the CMS EHR interoperability and digital quality measures proposal. (Source: The Rheumatologist)
Source: The Rheumatologist - September 14, 2021 Category: Rheumatology Authors: Natasha Yetman Tags: Practice Management Professional Topics American College of Rheumatology (ACR) fee Medicare Medicare Physician Fee Schedule (MPFS) telehealth telemedicine Source Type: research

Vasculitis Guidelines in Focus, Part 3: EGPA
In July, the ACR—in concert with the Vasculitis Foundation (VF)—released three new vasculitis guidelines, one each on: 1) anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, 2) giant cell arteritis and Takayasu arteritis, and 3) polyarteritis nodosa.1-3 The guideline development process is complex. For the vasculitis guidelines, this process kicked off in June 2017, when the core... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - September 14, 2021 Category: Rheumatology Authors: Michael Putman, MD Tags: Conditions Vasculitis EGPA eosinophilic granulomatosis with polyangiitis (EGPA) guideline Source Type: research

Rheum After 5: Dr. David Isenberg, Rheumatologist & Bandleader
In 2015, the Department of Immunology at the University College London (UCL) rented a room above the King & Queen pub in London for a seminar series. Among the speakers was David Isenberg, MD, FRCP (Fellow of the Royal College of Physicians), FAMS (Fellow of the Academy of Medical Sciences), who still serves as UCL’s academic... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - September 14, 2021 Category: Rheumatology Authors: Carol Patton Tags: Audio Rheum After 5 Dr. David Isenberg Source Type: research

New Editor Looks to Strengthen AC & R ’ s Connections to Clinical Care
Kelli Allen, PhD, believes strongly in the mission of AC&R, and as the journal’s new editor in chief, it’s now in her hands to carry that mission forward. Dr. Allen assumed the role on July 1, following the decade-long tenure of Dr. Hannan. “Everyone has been very generous with their time and the managing editors... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - September 14, 2021 Category: Rheumatology Authors: Kelly Tyrrell Tags: From the College AC&R Dr. Kelli Allen Source Type: research

Summer 2021 ’s Awards, Appointments & Announcements in Rheumatology
Marian Hannan Celebrated after 10 Years as AC&R Editor-in-Chief By Kelly April Tyrrell This summer, the 10-year tenure of Marian Hannan, MPH, DSc, as editor in chief of Arthritis Care & Research (AC&R), has come to an end. Kelli Allen, PhD, assumed the post on July 1. “Marian has done a fantastic job over the... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - September 14, 2021 Category: Rheumatology Authors: Kelly April Tyrrell & Gretchen Henkel Tags: Awards Profiles Dr. John J. O’Shea Dr. Marian Hannan Dr. Tuhina Neogi Source Type: research

HIPAA and PHI Cybersecurity Best Practices in the COVID-19 Era
When the first SARS-CoV-2 case was recorded, it was difficult to appreciate the extent to which cybersecurity concerns, particularly in connection to the protection of patient healthcare data, would enter into main­stream consciousness. Although many practices and healthcare organizations have recently adopted additional measures to safeguard patients’ protected health information (PHI) through expanded cybersecurity monitoring,... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - September 14, 2021 Category: Rheumatology Authors: Steven M. Harris, Esq. Tags: Legal HIPAA protected health information Source Type: research

Using Different Fibromyalgia Criteria Affects Prevalence Estimates
A recent paper illustrates how using different fibromyalgia criteria affects reports of its prevalence.1 Writing in Arthritis Care & Research, researchers found the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks–American Pain Society Pain Taxonomy (AAPT) criteria caused far more people to be categorized as having fibromyalgia than criteria put forth by... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - September 14, 2021 Category: Rheumatology Authors: Deborah Levenson Tags: Conditions Soft Tissue Pain Classification Criteria Fibromyalgia Source Type: research

COVID-19 & Pediatric Rheumatology
PRSYM 2021—Although primary COVID-19 infection has the most significant complications in adult patients, pediatric rheumatologists have also seen significant changes in their practice over the past year. With the emergence of COVID-19, the rise of a mysterious post-COVID hyper­inflammatory syndrome, now known as multisystem inflammatory syndrome in children (MIS-C), was identified, and pediatric rheumatologists have... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - September 14, 2021 Category: Rheumatology Authors: Elizabeth Sloan, MD Tags: Conditions COVID-19 Multisystem Inflammatory Syndrome in Children (MIS-C) PRSYM Source Type: research

Minnesota Joins Dakotas to Form Growing Rheumatology Association
A relatively new state association, the Rheumatology Association of Minnesota and the Dakotas (RA-MD), held its first meeting in 2016. Five years later, the association president, Jody Hargrove, MD, a board-certified rheumatologist with Arthritis and Rheumatology Consultants PA, Edina, Minn., says the group’s membership fluctuates between 80 and 100 rheumatology professionals. RA-MD has members from... [Read More] (Source: The Rheumatologist)
Source: The Rheumatologist - September 14, 2021 Category: Rheumatology Authors: Linda Childers Tags: Legislation & Advocacy Professional Topics State Rheum telehealth Source Type: research